



Cytiva Industry Educational Session

Tuesday 25 June 2024

10:20 – 10:50

Room – Lammermuir 2

ELEVECTA cell lines for next-generation AAV manufacturing - Combining high scalability and increased quality by reducing encapsidated host cell DNA

Gene therapy has revolutionized human medicine for inherited diseases. Recombinant adeno-associated virus (AAV) has been used extensively to deliver transgenes in clinical studies. A major challenge is establishing production processes that can keep up with the increasing demand for quantity and quality of viral vectors.

Speaker: Michelle Hussong, Head of Molecular Biology and Analytics, Cytiva